Vaxcyte, Inc. 4

Elvia Cowan, SVP, Finance & CAO of Vaxcyte, Inc., surrendered 1,327 shares of common stock (≈$80K) to cover taxes upon RSU vesting, leaving her with 27,860 shares.

On September 8, 2026, Elvia Cowan, SVP, Finance & CAO of Vaxcyte, Inc., surrendered 1,327 shares of Vaxcyte common stock to the company at an implied price of $60.36 per share, for an aggregate value of approximately $80,100, to satisfy tax withholding obligations arising from the vesting of restricted stock units. This was an automatic, non-open-market disposition (Code F) and left her with beneficial ownership of 27,860 shares of common stock. The transaction reflects routine equity compensation tax withholding rather than a discretionary sale in the open market.

Filing Facts

CIK

1649094

Ticker

PCVX

Form

4

Source Type

fda

Accession

0001960048-26-000011

Alert Tier

5